相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study
Kyubok Jin et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Lower Apo A-I and Lower HDL-C Levels Are Associated With Higher Intermediate CD14++CD16+ Monocyte Counts That Predict Cardiovascular Events in Chronic Kidney Disease
Kyrill S. Rogacev et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study
Vincent M. Brandenburg et al.
ATHEROSCLEROSIS (2014)
Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
H. Abujrad et al.
ATHEROSCLEROSIS (2014)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Associations of FGF-23 and sKlotho with Cardiovascular Outcomes among Patients with CKD Stages 2-4
Sarah Seiler et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
Arjan J. Kwakernaak et al.
ATHEROSCLEROSIS (2013)
Calcium and phosphate impact cardiovascular risk
Gunnar H. Heine et al.
EUROPEAN HEART JOURNAL (2013)
Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
Daniel Urban et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Ron T. Gansevoort et al.
LANCET (2013)
Cholesterol Synthesis, Cholesterol Absorption, and Mortality in Hemodialysis Patients
Kyrill S. Rogacev et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Monocyte subpopulations and cardiovascular risk in chronic kidney disease
Gunnar H. Heine et al.
NATURE REVIEWS NEPHROLOGY (2012)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent et al.
LANCET (2011)
Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
C. Baigent et al.
AMERICAN HEART JOURNAL (2010)
Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease
P. Stenvinkel
JOURNAL OF INTERNAL MEDICINE (2010)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Bengt C. Fellstroem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
ND Vaziri
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
C Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study
P Muntner et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
分享论文
